Sequences in the cytoplasmic tail of SARS-CoV-2 Spike facilitate expression at the cell surface and syncytia formation by Cattin-Ortolá, Jérôme et al.
Open Access This file is licensed under a Creative Commons Attribution 4.0 
International License, which permits use, sharing, adaptation, distribution and 
reproduction in any medium or format, as long as you give appropriate credit to 
the original author(s) and the source, provide a link to the Creative Commons license, and indicate if 
changes were made. In the cases where the authors are anonymous, such as is the case for the reports of 
anonymous peer reviewers, author attribution should be to 'Anonymous Referee' followed by a clear 
attribution to the source work.  The images or other third party material in this file are included in the 
article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is 
not included in the article’s Creative Commons license and your intended use is not permitted by statutory 
regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright 
holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. 
Peer Review File
Editorial Note: This manuscript has been previously reviewed at another journal that is not 
operating a transparent peer review scheme. This document only contains reviewer comments and 
rebuttal letters for versions considered at Nature Communications. 
REVIEWERS' COMMENTS 
Reviewer #1 (Remarks to the Author): 
The Authors have addressed the concerns raised in my previous review by acknowledging the finding 
by Carolyn Machamer concerning the suboptimal binding of COPI by the Spike protein of SARS-CoV 
and by co-expressing the M protein with the Spike protein of SARS-CoV-2. Surprisingly while, as 
expected, the wt S protein is retained by and colocalizes with M protein in the Golgi complex, the 
H1271K and the T1273A S mutants neither are affected by the M protein nor they colocalize with it: 
have they lost the ability to interact with M? 
Reviewer #3 (Remarks to the Author): 
The work by Cattin-Ortolá, Welch and colleagues has been extensively expanded with new 
experimental data that further support their conclusions. The authors have responded in depth to 
our comments and have added substantial and important new data that addressed all our questions 
and concerns. 
Importantly, the authors have now shown the direct nature of Spike(S):COPI interaction by 
recapitulating the binding between purified recombinant β-COP (residues 1-304) and recombinant S 
tail. This result strengthens the previous immunoprecipitation experiments where recombinant S tail 
was used to immunoprecipitate COPI from HEK293T cell lysates (hence indirect association couldn’t 
be excluded). Moreover, the manuscript contains new data quantifying the effects that S tail 
mutations have on the binding to COPI/COPII. Further light microscopy-based imaging has also 
clarified the trafficking differences between wild type and mutant Spike proteins. 
By exploring the role of a suboptimal COPI binding motif in the cytosolic tail of SARS-CoV-2 Spike the 
authors report a cellular mechanism that could account for increased surface accumulation of Spike 
in infected cells. This process, in combination with other aspects of SARS-CoV-2 biology, might 
account for the fact that SARS-CoV-2 induces cell fusion more efficiently than SARS-CoV. SARS-CoV-2 
S trafficking and presentation to the cells surface is relevant for understanding the immunogenicity 
of S-based vaccines and exploring new antiviral approaches. Overall, we thank the authors for their 
work, and we recommend the publication of the manuscript in Nature Communications. 
Reviewer #4 (Remarks to the Author): 
The manuscript “Sequences in the cytoplasmic tail of SARS-CoV-2 Spike facilitate expression at the 
cell surface and syncytia formation” by Cattin-Ortola and colleagues investigates potential 
mechanism in which Spike accumulates at the cell surface. Their findings are unique and provide an 
important mechanistic advance in understanding syncytia formation by SARS-CoV-2. They suggest 
that suboptimal COPI-binding residues in the Spike protein allows for leakage from the Golgi which 
ultimately allows for plasma membrane accumulation and cell-cell fusion. 
In order to show that mutations in the Spike protein COPI binding site differentially affect syncytia 
formation, they perform an acceptor-donor experiment where human 293T cells transfected with 
spike protein are co-cultured with Vero cells expressing human ACE2. The previous reviewer had 
expressed concern regarding the physiological relevance of this model and editor has solicited our 
opinion on the matter. 
Generally speaking, the acceptor-donor syncytia formation system is used to assess the fusogenicity 
of the different spikes (WT vs mutants) and provides a quantifiable comparison and is not intended 
to replicate physiological syncytia formation. The transfection of the donor 293T cells with Spike is 
suitable because they do not express endogenous ACE2, thus preventing donor-donor fusion. The 
primary reason to use Vero cells as acceptors is for their endogenous ACE2 expression, albeit 
monkey ACE2, which reduced variations in intra/intercellular ACE2 expression. Endogenous Vero 
ACE2 expression by itself can induce cell-cell fusion with acceptor cells expressing spike. This would 
have been sufficient for the author’s intended characterization of mutant spike proteins. Thus, it is 
curious that the authors used Vero cells that are also expressing human ACE2. If their goal is to 
demonstrate spike mediated fusion specifically with the human ACE2 then using human cell lines like 
A549 or U2OS cells transduced with ACE2 as the acceptor cells would have been acceptable. 
However, as the author state that they are just assessing the degree of cell-cell fusion elicited by the 
spike mutants, the system used provides relevant information within its own confines. 
Response to reviewers’ comments.   
We are very pleased that the reviewers felt that we had done a good job in 
addressing their comments and concerns, and hence they were happy to 
recommend publication. To address the remaining concerns of Reviewers #1 and 
#4, we have, as requested, added further discussion in the text about the 
interaction between S and M, and also discussed the caveats of the cell fusion 
assay. We have also addressed all of the editorial requests, as outlined in our 
responses in the Author Checklist, and have ensured that the manuscript 
complies with the policies and formatting requirements of Nature 
Communications.   
 
Reviewer #1 (Remarks to the Author): 
The Authors have addressed the concerns raised in my previous review by acknowledging the 
finding by Carolyn Machamer concerning the suboptimal binding of COPI by the Spike 
protein of SARS-CoV and by co-expressing the M protein with the Spike protein of SARS-
CoV-2. Surprisingly while, as expected, the wt S protein is retained by and colocalizes with 
M protein in the Golgi complex, the H1271K and the T1273A S mutants neither are affected 
by the M protein nor they colocalize with it: have they lost the ability to interact with M? 
We have added further discussion in the results to address this issue, and the 
relevant section now reads:  
“Immunofluorescence shows that these variants still have the substantial ER 
staining seen in the absence of M (Supplementary Fig. 3c). In these cases, M does 
not accumulate in the ER as well, but rather is still localised to the Golgi. This is 
consistent with previous studies with other coronaviruses that found that S and 
M do not associate in the ER where they are both synthesised, but rather they 
only assemble after they have accumulated at the site of virion budding in the 
early Golgi20,42,43. Thus, even in the presence of M, the COPII binding site in S is 
required for exit from the ER, and an optimised COPI binding site in S can be 
recognised so as to reduce transport to the surface.” 
 
Reviewer #4 (Remarks to the Author): 
Thus, it is curious that the authors used Vero cells that are also expressing human ACE2. If 
their goal is to demonstrate spike mediated fusion specifically with the human ACE2 then 
using human cell lines like A549 or U2OS cells transduced with ACE2 as the acceptor cells 
would have been acceptable. However, as the author state that they are just assessing the 
degree of cell-cell fusion elicited by the spike mutants, the system used provides relevant 
information within its own confines.   
We have added further discussion in the results to make this caveat clear, and 
the relevant section now reads:  
“It should be noted that this assay was performed using as the fusion target 
monkey (Vero) cells overexpressing human ACE2. This will increase the 
susceptibility of the cells to S-mediated fusion, and hence it is striking that the 
H1271K mutant still reduces fusion, but it also means that caution is needed in 
extrapolating these findings to other cell types. Nonetheless, the results clearly 
indicate that, at least in this context, the sub-optimal COPI binding site enhances 
the ability of S to form syncytia.” 
